Neuronal induction of the immunoproteasome in Huntington's disease.
Huntington's disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies. This, together with proteasome activity studies on transfected cells, suggest that an impairment of the ubiquitin-proteasome system (UPS) may be key in HD pathogenesis. To test whether proteasome activity is impaired in vivo, we performed enzymatic assays for the three peptidase activities of the proteasome in brain extracts from the HD94 conditional mouse model of HD. We found no inhibition of any of the activities, suggesting that if UPS impairment happens in vivo, it is not at the level of the proteasome catalytic core. Intriguingly, the chymotrypsin- and trypsin-like activities increased selectively in the affected and aggregate-containing regions: cortex and striatum. Western blot analysis revealed no difference in total proteasome content whereas an increase in the interferon-inducible subunits of the immunoproteasome, LMP2 and LMP7, was observed. These subunits confer to the proteasome catalytic properties that are optimal for MHC-I peptide presentation. Immunohistochemistry in control mouse brain revealed LMP2 and LMP7 mainly in neurons. Accordingly, their increase in HD94 mice predominantly took place in neurons, and 5% of the ubiquitin-positive cortical aggregates were also LMP2-positive. Ultrastructural analysis of neurons with high level of immunoproteasome subunits revealed signs of neurodegeneration like nuclear indentation or fragmentation and dark cell appearance. The neuronal induction of LMP2 and LMP7 and the associated signs of neurodegeneration were also found in HD postmortem brains. Our results indicate that LMP2 and LMP7 participate in normal neuronal physiology and suggest a role in HD neurodegeneration.
Díaz-Hernández
Miguel
M
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Contoblanco, 28049 Madrid, Spain.
Hernández
Félix
F
Martín-Aparicio
Ester
E
Gómez-Ramos
Pilar
P
Morán
María A
MA
Castaño
José G
JG
Ferrer
Isidro
I
Avila
Jesús
J
Lucas
José J
JJ
D000368:Aged; D000818:Animals; D001921:Brain / Q000473:pathology; D002540:Cerebral Cortex / Q000201:enzymology; D002918:Chymotrypsin / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000201:enzymology* / Q000473:pathology; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009097:Multienzyme Complexes / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism; D017072:Neostriatum / Q000201:enzymology; D009474:Neurons / Q000201:enzymology* / Q000648:ultrastructure; D046988:Proteasome Endopeptidase Complex; D014357:Trypsin / Q000378:metabolism; D014452:Ubiquitins / Q000032:analysis
D009097:Multienzyme Complexes; D014452:Ubiquitins; C071313:LMP-2 protein; D002918:Chymotrypsin; D014357:Trypsin; D003546:Cysteine Endopeptidases; C077436:LMP7 protein; D046988:Proteasome Endopeptidase Complex